nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

27.04.2020 | COVID-19 | Editorial Zur Zeit gratis

Covid-19 treatment update: follow the scientific evidence

verfasst von: Richard C. Becker

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

“In questions of science, the authority of a thousand may not exceed the humble and careful reasoning of on individual.” Galileo Galilei

…

Morens DM, Daszak P, Taubenberger JK (2020) Escaping Pandora's box— another novel Coronavirus. N Eng J Med 382:1293–1295CrossRef

Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for disease control and prevention. JAMA.

Kupferschmidt K, Cohen J (2020) Race to find COVID-19 treatments accelerates. Science (New York, NY) 367:1412–1413CrossRef

Jakhar D, Kaur I (2020) Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med

Plowe CV (2005) Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr Top Microbiol Immunol 295:55–79

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis 3:722–727CrossRef

Boone BA, Murthy P, Miller-Ocuin J, Doerfler WR, Ellis JT, Liang X, Ross MA, Wallace CT, Sperry JL, Lotze MT, Neal MD, Zeh HJ 3rd (2018) Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC cancer 18:678CrossRef

Zhang Q, Tsuji-Hosokawa A, Willson C, Watanabe M, Si R, Lai N, Wang Z, Yuan JX, Wang J, Makino A (2020) Chloroquine differentially modulates coronary vasodilation in control and diabetic mice. Br J Pharmacol 177:314–327CrossRef

Yuan X, Xiao YC, Zhang GP, Hou N, Wu XQ, Chen WL, Luo JD, Zhang GS (2016) Chloroquine improves left ventricle diastolic function in streptozotocin-induced diabetic mice. Drug Des Dev Ther 10:2729–2737CrossRef

10.

Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42:145–153CrossRef

11.

Blignaut M, Espach Y, van Vuuren M, Dhanabalan K, Huisamen B (2019) Revisiting the cardiotoxic effect of chloroquine. Cardiovasc Drugs Ther 33:1–11CrossRef

12.

Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323:264–268CrossRef

13.

Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P (2009) Antiviral activity of chloroquine against human Coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53:3416–3421CrossRef

14.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271CrossRef

15.

Huang M, Tang T, Pang P, Li M, Ma R, Lu J, Shu J, You Y, Chen B, Liang J, Hong Z, Chen H, Kong L, Qin D, Pei D, Xia J, Jiang S and Shan H (2020) Treating COVID-19 with chloroquine. J Mol Cell Biol.

16.

Al-Bari MA (2015) Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70:1608–1621CrossRef

17.

Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38:653–671CrossRef

18.

Ohkuma S, Poole B (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75:3327–3331CrossRef

19.

Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L (1993) Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 20:803–808

20.

Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ (2000) Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 95:3460–3466CrossRef

21.

Fantini J, Scala CD, Chahinian H and Yahi N (2020) Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 105960.

22.

Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213–1218

23.

Ali M, Girgis S, Hassan A, Rudick S, Becker RC (2018) Inflammation and coronary artery disease: from pathophysiology to Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Coron Artery Dis 29:429–437CrossRef

24.

Newby AC (2015) Metalloproteinases promote plaque rupture and myocardial infarction: a persuasive concept waiting for clinical translation. Matrix Biol 44–46:157–166CrossRef

25.

Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89:322–326CrossRef

26.

Achuthan S, Ahluwalia J, Shafiq N, Bhalla A, Pareek A, Chandurkar N, Malhotra S (2015) Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: a proof of concept study. J Cardiovasc Pharmacol Ther 20:174–180CrossRef

27.

Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, Lou W, Fortin PR (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863–868CrossRef

28.

Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM (2018) Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41:919–931CrossRef

29.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W and Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis.

30.

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16CrossRef

31.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P and Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949.

32.

Woosley RL, Black K, Heise CW, Romero K (2018) CredibleMeds.org: What does it offer? Trends Cardiovasc Med 28:94–99CrossRef

33.

Dunker A, Kolanczyk DM, Maendel CM, Patel AR, Pettit NN (2016) Impact of the FDA Warning for Azithromycin and Risk for QT Prolongation on Utilization at an Academic Medical Center. Hosp Pharmacy 51:830–833CrossRef

34.

Thind M, Rodriguez I, Kosari S, Turner JR (2020) How to prescribe drugs with an identified proarrhythmic liability. J Clin Pharmacol 60:284–294CrossRef

35.

Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V (2017) Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm 39:424–432CrossRef

36.

Borba M, Val FdA, Sampaio VS, Alexandre MA, Melo GC, Brito M, Mourao M, Brito Sousa JD, Baia-da-Silva d, Guerra MVF, Hajjar L, Pinto RC, Balieiro A, Naveca FG, Xavier M, Salomao A, Siqueira A, Schwarzbolt A, Croda JHR, Nogueira ML, Romero G, Bassat Q, Fontes CJ, Albuquerque B, Daniel-Ribeiro C, Monteiro W and Lacerda M (2020) Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. 2020.04.07.20056424.

37.

Kieny MP, Salama P (2017) WHO R&D Blueprint: a global coordination mechanism for R&D preparedness. Lancet 389:2469–2470CrossRef

38.

Woodcock J, LaVange LM (2017) Master protocols to study multiple therapies, multiple diseases, or both. N Eng J Med 377:62–70CrossRef

Titel: Covid-19 treatment update: follow the scientific evidence
verfasst von: Richard C. Becker
Publikationsdatum: 27.04.2020
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 1/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02120-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Covid-19 treatment update: follow the scientific evidence

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

The risk of intramuscular haematoma is low following injection of benzathine penicillin G in patients receiving concomitant anticoagulant therapy

Characterization of circulating thrombin in patients with septic shock: a prospective observational study

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism

Congenital hypofibrinogenemia associated with a novel heterozygous nonsense mutation in the globular C-terminal domain of the γ-chain (p.Glu275Stop)

Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report

COVID-19: Plötzlicher Tod aufgrund einer Lungenembolie

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin